The Efficacy of Sintilimab Combined with Platinum-based Chemotherapy in the Treatment of Advanced NSCLC Patients and Its Influence on Serum Notch1 and Dickkopf-1 Levels
Kang Lihua, Zhai Fengyu, Liu Yuefen
Department of Oncology,Puyang Oilfield General Hospital,Puyang,Henan 457000,China
Abstract：Objective To observe the efficacy of sintilimab combined with platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)patients and its impact on serum Notch1 and Dickkopf-1 levels. Methods A total of 106 patients with advanced NSCLC admitted from selected and randomly divided into two groups using a random number table.The single group was treated with platinum-based chemotherapy,while the combination group was treated with sintilimab combined with platinum-based chemotherapy.The objective response rate,disease control rate,Notch1 mRNA,Dickkopf-1,T lymphocyte subsets,tumor markers,and adverse reaction rates were compared between the two groups. Results The disease control rate was higher in the combination therapy group than in the single-agent group(P<0.05).There was no significant difference in objective response rates between the two groups(P>0.05).Pre-treatment study-related indicators showed no significant differences between the two groups(P>0.05).After three treatment cycles,both groups showed decreased Notch1 mRNA and Dickkopf-1 levels compared to baseline.The combined therapy group exhibited lower levels than the single-agent group after three cycles(P<0.05).After three treatment cycles,the combined therapy group exhibited higher CD3+,CD4+,and CD4+/CD8+ ratios compared to pre-treatment levels and the monotherapy group after three cycles.Conversely,CD8+ levels were lower than pre-treatment and monotherapy group levels after three cycles(P<0.05).No significant differences were observed in T lymphocyte subsets between monotherapy groups before and after treatment(P>0.05).After three treatment cycles,both groups showed decreased levels of carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA),and carcinoembryonic antigen(CEA)compared to baseline.The combined therapy group exhibited lower levels than the single-therapy group after three cycles(P<0.05).The incidence of adverse reactions was comparable between groups(3.77% in the single-agent group vs.7.55%in the combination group;P>0.05). Conclusion Sintilimab combined with platinum-based chemotherapy in the treatment of advanced NSCLC can improve immune function,inhibit the expression of Notch1,Dickkopf-1,and tumor markers,and increase the objective response rate.
康丽花, 翟凤钰, 刘月芬. 信迪利单抗联合含铂化疗治疗晚期NSCLC患者的疗效及对血清Notch1、Dickkopf-1水平的影响[J]. 哈尔滨医药, 2026, 46(1): 20-24.
Kang Lihua, Zhai Fengyu, Liu Yuefen. The Efficacy of Sintilimab Combined with Platinum-based Chemotherapy in the Treatment of Advanced NSCLC Patients and Its Influence on Serum Notch1 and Dickkopf-1 Levels. journal1, 2026, 46(1): 20-24.
2026, Vol. 46 
